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Obstructive sleep apnea is common in patients with heart 
failure. This case illustrates that treatment with PAP therapy 
can improve cardiac function in patients with both conditions. 
CPAP-emergent central apnea, as seen in this patient, has 
multiple etiologies. It is commonly seen in patients with severe 
sleep apnea, usually resolves over time, and does not need 
treatment with adaptive servoventilation.
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Obstructive sleep apnea (OSA) is a common condition with high rates of morbidity and mortality.1 The prevalence 
of this disease has increased substantially, along with the cost 
of diagnosing and treatment of this condition.2 Despite its as-
sociation with cardiovascular diseases, sleep apnea remains 
underdiagnosed in patients with heart disease.3,4 Meanwhile, 
there has been increased development and promotion of new, 
advanced, and more expensive devices by industry to treat 
sleep apnea despite the lack of any evidence that these devices 
have superior clinical outcomes.5 Following is a case which 
highlights both these issues.
repOrt Of CaSe
TC, a 44-year-old obese African American male with a BMI 
of 41, longstanding history of hypertension, non-smoker, with 
no history of alcohol use, and a 2-3 year history of progres-
sively increasing shortness of breath and cough, was diagnosed 
with New York Heart Association (NYHA) class III heart fail-
ure (HF) in July 2008. Electrocardiogram (ECG) fi ndings were 
notable for biatrial abnormality and borderline left ventricular 
(LV) hypertrophy, with no evidence of heart block. Echocar-
diogram showed severe dilation and global hypokinesis of LV 
with a LV ejection fraction (LVEF) of 10% and moderately re-
duced right ventricular (RV) function. Left heart catheteriza-
tion did not show any occlusive coronary artery disease. Right 
heart catheterization showed elevated right atrial (RA) pressure 
at 17 mm Hg, pulmonary capillary wedge pressure (PCWP) of 
30 mm Hg, pulmonary artery (PA) pressure of 74/30 mm Hg, 
and severely reduced right ventricular (RV) function. Cardio-
pulmonary exercise test showed maximum oxygen consump-
tion (VO2) of 12 cc/kg/minute. His clinical presentation was 
consistent with idiopathic dilated cardiomyopathy of unknown 
etiology. An endomyocardial biopsy was not performed to rule 
out any treatable causes of heart failure, in keeping with current 
recommendations by the American Heart Association/Ameri-
can college of Cardiology (AHA/ACC).6 He was treated with 
aspirin and maximal tolerated doses of ACE receptor inhibitor, 
β-blocker, and a diuretic. An ICD (implantable cardioverter-
defi brillator) was placed, and he was evaluated and placed on 
the cardiac transplant list.
Due to his longstanding history of snoring, witnessed ap-
neas, and excessive daytime sleepiness (Epworth Sleepiness 
Scale [ESS] score of 17), he was evaluated for OSA in De-
cember 2008. Polysomnography, performed with a split-night 
protocol revealed an apnea-hypopnea index (AHI) of 68 with 
a SaO2 nadir of 58%. Respiratory events were all obstructive 
in nature with no central apneas. Continuous positive airway 
pressure (CPAP) titration to a maximum pressure of 20 cm 
H2O was unsuccessful in controlling the obstructive respira-
tory events. He was also noted to develop central apneas, not 
present on diagnostic polysomnography, along with a high leak 
with increasing pressures. He was prescribed a bilevel device, 
set at a maximum pressure of 25/21 cm water pressure, after a 
retitration study in the sleep laboratory, during which a pres-
sure of 28/23 cm water was insuffi cient to control obstructive 
apneas and hypopneas. This was again associated with central 
apneas on increasing the pressures (so called CPAP-emergent 
central apnea). Signifi cantly, he had evidence of high leak on 
both titration studies.
On subsequent follow-up appointments, he demonstrated 
fairly good compliance of > 80% with his bilevel device, de-
spite complaints of dry mouth. He continued to have a high 
leak, along with an elevated AHI of 15-17 on download of 
smart card data. The patient had diffi culty tolerating the high 
pressures, and at one point tracheostomy was considered for 
control of apneas but rejected by the transplant team due to fear 
of infection following transplant, as the patient would be on 
immunosuppressants.
He underwent an adaptive servoventilation (ASV) titration 
study in October 2009. Expiratory positive airway pressure 
(EPAP) was titrated to 18 cm water pressure with elimination 
of all obstructive apneas and hypopneas. During this study he 
had minimal leak and no evidence of central apneas as EPAP 
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were treated had a better 2-year survival rate than those who 
were not treated.18
It is now recommended that physicians caring for patients 
with heart failure need to be aware of the presence of OSA and 
its effect on causing progression of heart failure, along with the 
role of treatment of sleep apnea and other therapies for heart 
failure.19,20 An expert consensus statement from the AHA/ACC 
recommends that with the current epidemic of obesity, hyper-
tension, and heart failure, the prevalence and consequences of 
OSA are likely to increase. There needs to be an increased inter-
action between sleep specialists and cardiologists in diagnosing 
and treating this condition.21
Second, this case also highlights a possible etiology of CPAP 
-emergent central apnea. Several hypotheses have been pro-
posed to explain CPAP-emergent central apnea; most of these 
hypotheses suggest that CPAP -emergent central apnea resolves 
over time.22 It has been shown in one study of patients with 
both OSA and CHF to be related to a high respiratory controller 
gain prior to application of CPAP.23 A high leak leading to CO2 
washout could also be responsible. It may be due to the chang-
es in CO2 excretion that occur with relief of the upper airway, 
leading to a fall in pCO2 below the apneic threshold.
24 Sleep 
fragmentation with frequent sleep-wake transitions occurring 
with initiation of CPAP can lead to central apneas.25 Adaptive 
servoventilation (ASV) has been shown to be superior to CPAP 
in treating central sleep apnea, but there have been no long-term 
studies showing superior clinical outcomes.26,27 There are cur-
rently two ongoing multicenter, randomized controlled trials, 
ADVENT-HF and SERVE-HF,31 to evaluate the cost effective-
ness and efficacy of ASV in treating patients with heart failure 
and central sleep apnea.
It is my view that this patient developed a dilated non-isch-
emic cardiomyopathy, most likely due to severe untreated OSA, 
with hypertension and hypoxemia, present for many years. It is 
possible that other etiologies of heart failure such as viral myo-
carditis, sarcoidosis, and rare conditions like amyloidosis and 
hemochromatosis may have been present, and an endomyocar-
dial biopsy would have better elucidated the cause of heart fail-
ure.6 However, the clinical scenario presented strongly suggests 
that the cause of heart failure in this patient was obstructive 
sleep apnea. Treatment of OSA with PAP therapy, along with 
the associated improvement in hypoxemia, in conjunction with 
medical therapy for hypertension and heart failure contributed 
significantly to improved cardiac function to the extent that he 
did not require a cardiac transplant.
With PAP therapy, he developed central apneas, possibly due 
to a high leak. Over time, central apneas were no longer pres-
ent as evidenced by smart card data with no use of PS (PS of 2 
being insignificant) and all breaths being patient triggered. PAP 
requirements to keep the upper airway open were reduced to a 
much lower level along with minimal leak. This may have been 
due to increased compliance and volume of the upper airway,28 
partly due to improved ejection fraction, with reduced conges-
tion of the upper airway. Reduced CPAP pressures requirements 
may also be due to reduced collapsibility of the upper airway 
with increasing lung volume from continued CPAP use,29 loss 
of weight, and decreased heart size. It is possible that reduced 
inflammation of the upper airway over time with CPAP use may 
have played a role.28,30 It is important to note that this patient 
pressures were being increased. He was prescribed an ASV 
machine, set with a minimum EPAP of 18 cm, maximum in-
spiratory positive airway pressure (IPAP) of 25 cm, minimum 
pressure support (PS) of 0, maximum PS of 7, and a backup 
respiratory rate of 10.
Despite all the problems with PAP therapy during this year, 
his symptoms of OSA and heart failure improved. NYHA func-
tional class improved from Class III to Class I over the next 
year. VO2 increased from 12 cc/kg/min at initial evaluation to 
20 cc/kg/min two years later. Repeat echocardiograms at pe-
riodic intervals showed gradually improving cardiac function. 
Echocardiogram with Doppler done in June 2011 showed mild 
global LV dysfunction, with a LVEF at 45% to 50%. There was 
mild LA and LV enlargement. RA and RV were normal with 
significant reduction of estimated PA systolic pressure to 30 mm 
Hg. Daytime sleepiness was no longer present, with improve-
ment of ESS to 5. He no longer required a cardiac transplant.
Download of smart card data on subsequent appointments 
showed no leak, with complete control of apneas at an EPAP 
average device pressure of 18 cm for ≤ 90% of time and aver-
age PS of 2. All breaths were patient triggered. In other words, 
this device was functioning as a CPAP machine set at a fixed 
pressure of 18 cm (minimum EPAP was set at 18), with no leak 
and complete control of apneas.
DISCUSSION
This case is interesting because it highlights a number of im-
portant points. First is the association of obstructive sleep apnea 
with heart failure. Sleep disordered breathing (OSA and central 
sleep apnea) is common in patients with heart failure, but the 
diagnosis is frequently missed, as the typical symptoms of OSA 
may not be present.7 The prevalence can be as high as 50% 
in patients with reduced ejection fraction.8 In the Sleep Heart 
Health Study, a large prospective, multicenter observational co-
hort study over 9 years, obstructive sleep apnea was associated 
with an increased risk of incident heart failure in both middle-
aged and elderly males and reduced survival in younger males.9 
There was also a dose-response relationship, with a higher AHI 
being associated with a greater risk of developing heart failure 
as well as increased mortality. In one observational study of 296 
patients with severely reduced cardiac function (median LVEF 
of 33%), patients with severe sleep disordered breathing had a 
2-fold increased risk for death, which improved in the patients 
who were treated with CPAP.10
OSA may worsen cardiac function by increasing afterload 
due to the negative intrathoracic pressure generated during re-
spiratory efforts against an occluded upper airway.11 Sleep ap-
nea has also been shown to cause progression of heart failure 
possibly due to intermittent hypoxia.12,13 It is well known that 
cardiac function improves with PAP therapy.14,15 This is not 
only as a consequence of positive intrathoracic pressure reduc-
ing transmural pressure, which reduces afterload, but preload is 
also reduced. Both lead to improvement in ejection fraction.16,17 
In a retrospective study of over 30,719 Medicare beneficiaries 
with heart failure, those who were tested, diagnosed, and treat-
ed for OSA had a better 2-year survival rate than subjects with 
heart failure who were not tested for OSA. Similarly, among 
subjects who were tested and diagnosed with OSA, those who 
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was treated with an ASV device, which eventually functioned 
as a CPAP machine.
In conclusion, this case should heighten the awareness of 
the association of heart failure and OSA. It also illustrates the 
improvement in cardiac function with positive pressure thera-
py. CPAP-emergent central apnea has multiple etiologies, and 
in most patients resolves over time, and does not need to be 
treated. Finally, pressure requirements to treat severe OSA may 
decrease over time.
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